C2 Therapeutics raises $11.6M for esophageal ablation

C2 Therapeutics raised $11.6 million from 44 investors to help advance its Coldplay Focal Cryoballoon Ablation System to treat Barrett's esophagus. It has previously raised about $10 million since 2007, according to SEC filings. In May, the startup presented data for its handheld device that showed that 90% of treated patients in a 44-patient study had partial or complete regeneration from Barrett's to normal tissue. Barrett's esophagus is a result of chronic injury from gastroesophageal reflux disease. Over time, the normal esophageal lining is replaced with abnormal cells, putting patients at greater risk of cancer. More

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.